hrcak mascot   Srce   HID

Stručni rad

RETROSPECTIVE DATA ANALYSIS OF THE PATIENTS WITH INFLAMMATORY JOINT DISEASES TREATED WITH GOLIMUMAB IN CROATIA

Branimir Anić
Đurđica Babić-Naglić
Simeon Grazio
Tatjana Kehler
Dušanka Martinović Kaliterna
Ksenija Maštrović Radončić
Jadranka Morović-Vergles
Srđan Novak
Višnja Prus
Tonko Vlak
Marko Barešić

Puni tekst: hrvatski, pdf (1 MB) str. 0-0 preuzimanja: 182* citiraj
APA 6th Edition
Anić, B., Babić-Naglić, Đ., Grazio, S., Kehler, T., Martinović Kaliterna, D., Maštrović Radončić, K., ... Barešić, M. (2015). RETROSPEKTIVNA ANALIZA PODATAKA BOLESNIKA OBOLJELIH OD UPALNIH REUMATSKIH BOLESTI U HRVATSKOJ LIJEČENIH GOLIMUMABOM. Reumatizam, 62 (1), 0-0. Preuzeto s https://hrcak.srce.hr/182711
MLA 8th Edition
Anić, Branimir, et al. "RETROSPEKTIVNA ANALIZA PODATAKA BOLESNIKA OBOLJELIH OD UPALNIH REUMATSKIH BOLESTI U HRVATSKOJ LIJEČENIH GOLIMUMABOM." Reumatizam, vol. 62, br. 1, 2015, str. 0-0. https://hrcak.srce.hr/182711. Citirano 05.12.2020.
Chicago 17th Edition
Anić, Branimir, Đurđica Babić-Naglić, Simeon Grazio, Tatjana Kehler, Dušanka Martinović Kaliterna, Ksenija Maštrović Radončić, Jadranka Morović-Vergles, et al. "RETROSPEKTIVNA ANALIZA PODATAKA BOLESNIKA OBOLJELIH OD UPALNIH REUMATSKIH BOLESTI U HRVATSKOJ LIJEČENIH GOLIMUMABOM." Reumatizam 62, br. 1 (2015): 0-0. https://hrcak.srce.hr/182711
Harvard
Anić, B., et al. (2015). 'RETROSPEKTIVNA ANALIZA PODATAKA BOLESNIKA OBOLJELIH OD UPALNIH REUMATSKIH BOLESTI U HRVATSKOJ LIJEČENIH GOLIMUMABOM', Reumatizam, 62(1), str. 0-0. Preuzeto s: https://hrcak.srce.hr/182711 (Datum pristupa: 05.12.2020.)
Vancouver
Anić B, Babić-Naglić Đ, Grazio S, Kehler T, Martinović Kaliterna D, Maštrović Radončić K i sur. RETROSPEKTIVNA ANALIZA PODATAKA BOLESNIKA OBOLJELIH OD UPALNIH REUMATSKIH BOLESTI U HRVATSKOJ LIJEČENIH GOLIMUMABOM. Reumatizam [Internet]. 2015 [pristupljeno 05.12.2020.];62(1):0-0. Dostupno na: https://hrcak.srce.hr/182711
IEEE
B. Anić, et al., "RETROSPEKTIVNA ANALIZA PODATAKA BOLESNIKA OBOLJELIH OD UPALNIH REUMATSKIH BOLESTI U HRVATSKOJ LIJEČENIH GOLIMUMABOM", Reumatizam, vol.62, br. 1, str. 0-0, 2015. [Online]. Dostupno na: https://hrcak.srce.hr/182711. [Citirano: 05.12.2020.]

Sažetak
Golimumab is a human monoclonal antibody which inhibits
tumor necrosis factor-alpha (TNF-α) and is approved
for the treatment of infl ammatory arthritides (rheumatoid
arthritis, psoriatic arthritis and ankylosing spondylitis)
when the conventional non-pharmacological and pharmacological
therapies fail to cause remission or low disease
activity.
In this retrospective study there were included patients
with rheumatoid arthritis, psoriatic arthritis and ankylosing
spondylitis who were treated in Croatia with golimumab,
from June 2011 to June 2013. included and these retrospective
data are compared with similar data from clinical
trials and other available databases. Standard variables
of disease activity and functional ability were observed. Results demonstrated signifi cant effi cacy of golimumab
regarding lowring the disease activity and imrpving functional
ability in pateints with these infl ammatory rherumatic
disease.
In conclusion, in this retrospective study during two years
treatment golimumab showed effi cacy in decreasing disease
activity and imrpove functional ability in patiemts with
rheumatoid arthritis, psoriatic arthritis and ankylosing
spondylitis.

Ključne riječi
TNF-α inhibitors; golimumab; rheumatoid arthritis; psoriatic arthritis; ankylosing spondylitis; treatment; Croatia

Hrčak ID: 182711

URI
https://hrcak.srce.hr/182711

[hrvatski]

Posjeta: 360 *